Trial record 1 of 1 for:    NCT01409135
Previous Study | Return to List | Next Study

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

This study has been completed.
Agensys, Inc.
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: July 29, 2011
Last updated: October 6, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)